DBVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as DBVTF

DBV Technologies S.A.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 16, 2026

$8.97−0.08 (-0.88%)

Close on Oct 19, 2026

Market cap: $3.89B
P/E (TTM): –
Dividend yield: –

DBV Technologies S.A. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	5.64	4.15	16	4.84	5.71	11	15	–	–	–	–
Research & Development	117	89	60	76	70	102	115	–	–	–	–
Selling, General & Admin	36	31	32	26	35	45	71	–	–	–	–
Selling & Marketing	3.22	2.66	2.44	1.61	4.39	9.88	22	–	–	–	–
General & Administrative	33	29	30	24	31	35	49	–	–	–	–
Operating Expenses	153	121	92	101	104	170	186	–	–	–	–
Operating Income	-147	-117	-76	-97	-99	-159	-171	–	–	–	–
Merger & Restructuring Charges	–	–	–	–	0	24	–	–	–	–	–
Pretax Income	-146	-114	-73	-96	-98	-160	-171	–	–	–	–
Income Tax Expense	0.49	0.06	0.01	0.07	-0.38	-0.01	0.61	–	–	–	–
Net Income	-147	-114	73	96	-98	-160	-172	–	–	–	–
Net Income to Common	-147	-114	-73	-96	-98	-160	-172	–	–	–	–
EPS (Basic)(per share)	-1.05	-1.17	-0.76	-1.24	-1.78	-2.95	-4.65	–	–	–	–
EPS (Diluted)(per share)	-1.05	-1.17	-0.76	-1.24	-1.78	-2.95	-4.65	–	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	140	97	95	77	55	54	37	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	140	97	95	77	55	54	37	28,925	24,757	24	22
EBITDA	-144	-114	-73	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -3543.1%
Net margin: -3506.5%
Return on equity, FY2025: -149.8%

Financial strength

Current ratio: 3.72
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 322.1%

Valuation

P/E ratio: –
Price to sales: 774.82
Price to book: 24.24
Dividend yield: –